Indivior Out-Licenses China Rights To Opioid Treatment in $122.5 Million Pact

Indivior, a UK spinout from Reckitt Benckiser, will out-license China rights for its Sai Bo Song opioid addiction tablet to Zhejiang Pukang Biotech in a deal worth up to $122.5 million. Sai Bo Song is a combination of buprenorphine and naloxone, known as Suboxone in non-China markets. Indivior developed Suboxone, but its patent protection on the original formulation has expired. The company is now focused on developing Sublocade, its once-monthly injection of Suboxone, in non-China markets, and Perseris, a once-monthly form of Risperidone for schizophrenia. More details.... Share this with colleagues: // //